TNSN04168A1 - Derives de thiazole et d'oxazole qui modulent l'activite de ppar - Google Patents

Derives de thiazole et d'oxazole qui modulent l'activite de ppar

Info

Publication number
TNSN04168A1
TNSN04168A1 TNP2004000168A TNSN04168A TNSN04168A1 TN SN04168 A1 TNSN04168 A1 TN SN04168A1 TN P2004000168 A TNP2004000168 A TN P2004000168A TN SN04168 A TNSN04168 A TN SN04168A TN SN04168 A1 TNSN04168 A1 TN SN04168A1
Authority
TN
Tunisia
Prior art keywords
thiazole
oxazole derivatives
compounds
ppar activity
present
Prior art date
Application number
TNP2004000168A
Other languages
English (en)
Inventor
Noe Ouano Erasga
Gary Frederick Filzen
Andrew George Geyer
Chitase Lee
Bharat Kalidas Trivedi
Xue-Min Cheng
Original Assignee
Warner-Lambert Company Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company Llc filed Critical Warner-Lambert Company Llc
Publication of TNSN04168A1 publication Critical patent/TNSN04168A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/26—Radicals substituted by sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention fait connaitre des composés qui modifient l'activité de PPAR. La présente invention fait connaître également des sels pharmaceutiquement acceptables les composés; des compositions pharmaceutiquement acceptables comprenant les composés ou leurs ou leurs sels; et des méthodes pour leur utilisation comme agents thérapeutiques a des fins de traitement ou de prévention de l'hyperlipidémie et de l'hypercholestérolémie chez un mammifère. La présente invention fait connaître également des procédés pour la préparation des composés décrits.
TNP2004000168A 2002-03-07 2004-09-03 Derives de thiazole et d'oxazole qui modulent l'activite de ppar TNSN04168A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36240202P 2002-03-07 2002-03-07
PCT/IB2003/000708 WO2003074050A1 (fr) 2002-03-07 2003-02-24 Derives de thiazole et d'oxazole qui modulent l'activite de ppar

Publications (1)

Publication Number Publication Date
TNSN04168A1 true TNSN04168A1 (fr) 2007-03-12

Family

ID=27789157

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2004000168A TNSN04168A1 (fr) 2002-03-07 2004-09-03 Derives de thiazole et d'oxazole qui modulent l'activite de ppar

Country Status (29)

Country Link
US (1) US20030207924A1 (fr)
EP (1) EP1482935B1 (fr)
JP (1) JP2005528348A (fr)
KR (1) KR20040091693A (fr)
AP (1) AP2004003124A0 (fr)
AR (1) AR038881A1 (fr)
AT (1) ATE405260T1 (fr)
AU (1) AU2003206059A1 (fr)
BR (1) BR0308277A (fr)
CA (1) CA2478520A1 (fr)
CO (1) CO5601012A2 (fr)
DE (1) DE60323060D1 (fr)
EA (1) EA200400943A1 (fr)
EC (1) ECSP045285A (fr)
ES (1) ES2310650T3 (fr)
HN (1) HN2003000090A (fr)
IS (1) IS7377A (fr)
MA (1) MA27181A1 (fr)
MX (1) MXPA04007564A (fr)
NO (1) NO20044242L (fr)
OA (1) OA12780A (fr)
PA (1) PA8567801A1 (fr)
PE (1) PE20030989A1 (fr)
PL (1) PL372969A1 (fr)
TN (1) TNSN04168A1 (fr)
TW (1) TW200305403A (fr)
UY (1) UY27695A1 (fr)
WO (1) WO2003074050A1 (fr)
ZA (1) ZA200406068B (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6833380B2 (en) 2002-03-07 2004-12-21 Warner-Lambert Company, Llc Compounds that modulate PPAR activity and methods of preparation
US6875780B2 (en) 2002-04-05 2005-04-05 Warner-Lambert Company Compounds that modulate PPAR activity and methods for their preparation
US7244763B2 (en) * 2003-04-17 2007-07-17 Warner Lambert Company Llc Compounds that modulate PPAR activity and methods of preparation
MY150088A (en) 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
US7060697B2 (en) * 2003-05-19 2006-06-13 Irm Llc Immunosuppressant compounds and compositions
CN1946666A (zh) * 2004-02-27 2007-04-11 埃姆艮股份有限公司 用于治疗代谢性疾病的化合物、药物组合物和方法
ATE486055T1 (de) 2004-05-05 2010-11-15 High Point Pharmaceuticals Llc Neue verbindungen, ihre herstellung und verwendung
JP4981662B2 (ja) 2004-05-05 2012-07-25 ハイ・ポイント・ファーマスーティカルズ、エルエルシー 新規の化合物、その製法と使用
US7456164B2 (en) 2004-05-07 2008-11-25 Pfizer, Inc 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands
AU2012200214B2 (en) * 2004-05-14 2013-10-24 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
CA2567437A1 (fr) * 2004-05-25 2005-12-08 Metabolex, Inc. Triazoles substitues comme modulateurs de ppar et methodes de preparation
JP2008500358A (ja) * 2004-05-25 2008-01-10 メタボレックス インコーポレーティッド Ｐｐａｒのモジュレーターとしての、二環式の置換されたトリアゾール、およびこれらの調製方法
US7982050B2 (en) * 2005-05-07 2011-07-19 Seoul National University Industry Foundation Process for preparing ligands of PPARdelta and the intermediate compounds for preparing the same
US7465804B2 (en) * 2005-05-20 2008-12-16 Amgen Inc. Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders
RU2412935C2 (ru) 2005-06-30 2011-02-27 Хай Пойнт Фармасьютикалс, ЛЛС Феноксиуксусные кислоты в качестве активаторов дельта рецепторов ppar
WO2007013689A1 (fr) * 2005-07-29 2007-02-01 Takeda Pharmaceutical Company Limited Composé d'acide cyclopropanecarboxylique
AU2006291234A1 (en) 2005-09-14 2007-03-22 Amgen Inc. Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders
EP2386540A1 (fr) 2005-12-22 2011-11-16 High Point Pharmaceuticals, LLC Nouveaux composés, leur utilisation et préparation
JP2009132620A (ja) * 2006-03-07 2009-06-18 Astellas Pharma Inc フェニルチアゾール誘導体
WO2007101864A2 (fr) 2006-03-09 2007-09-13 High Point Pharmaceuticals, Llc Nouveaux composés, leur préparation et utilisation
CA2662305C (fr) 2006-09-07 2012-04-17 Amgen Inc. Modulateurs heterocycliques du recepteur couple a la proteine g (gpr40)
EP2061760A1 (fr) 2006-09-07 2009-05-27 Amgen, Inc Composés benzo-fusionnés destinés à être utilisés dans le traitement de troubles métaboliques
EP2139843B1 (fr) 2007-04-16 2013-12-25 Amgen, Inc Modulateurs de gpr40 des acides biphényle phénoxy, thiophényle et aminophénylpropanoïque substitués
KR20100090249A (ko) 2007-10-10 2010-08-13 암젠 인크 치환된 비페닐 ｇｒｐ４０ 조절제
AU2008338963A1 (en) * 2007-12-13 2009-06-25 Sri International PPAR-delta ligands and methods of their use
AU2008345573B2 (en) 2007-12-20 2013-12-19 Envivo Pharmaceuticals, Inc. Tetrasubstituted benzenes
JP2011515341A (ja) 2008-03-06 2011-05-19 アムジエン・インコーポレーテツド 代謝障害の治療に有用な立体配座的に制限されたカルボン酸誘導体
EP2358656B1 (fr) 2008-10-15 2014-01-01 Amgen, Inc Modulateurs spirocycliques de gpr40
JP2013525267A (ja) * 2010-02-25 2013-06-20 エスエヌユー アール＆ディービー ファウンデーション ペルオキシソーム増殖剤活性化受容体リガンドのセレナゾール誘導体、その製造方法及びその化合物の用途
CA2923422C (fr) 2013-09-09 2021-09-07 Vtv Therapeutics Llc Utilisation d'un agoniste de ppar-delta pour le traitement d'une amyotrophie
WO2023147309A1 (fr) 2022-01-25 2023-08-03 Reneo Pharmaceuticals, Inc. Utilisation d'agonistes ppar-delta dans le traitement d'une maladie

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859051A (en) * 1996-02-02 1999-01-12 Merck & Co., Inc. Antidiabetic agents
CN1233241A (zh) * 1996-08-19 1999-10-27 日本烟草产业株式会社 丙酸衍生物及其用途
GB9914977D0 (en) * 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
GB0031107D0 (en) * 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
EP1345916A1 (fr) * 2000-12-20 2003-09-24 Glaxo Group Limited Oxazoles et thiazoles substitues utiles en tant qu'agonistes de hppar alpha
GB0111523D0 (en) * 2001-05-11 2001-07-04 Glaxo Group Ltd Chemical compounds
US7282501B2 (en) * 2001-06-07 2007-10-16 Eli Lilly And Company Modulators of peroxisome proliferator activated receptors (PPAR)

Also Published As

Publication number Publication date
PE20030989A1 (es) 2003-11-29
UY27695A1 (es) 2003-10-31
ZA200406068B (en) 2005-09-06
IS7377A (is) 2004-07-29
EP1482935A1 (fr) 2004-12-08
JP2005528348A (ja) 2005-09-22
ECSP045285A (es) 2004-10-26
OA12780A (en) 2006-07-07
MXPA04007564A (es) 2004-11-10
CA2478520A1 (fr) 2003-09-12
TW200305403A (en) 2003-11-01
NO20044242L (no) 2004-10-06
PL372969A1 (en) 2005-08-08
ES2310650T3 (es) 2009-01-16
AU2003206059A1 (en) 2003-09-16
HN2003000090A (es) 2004-05-05
AP2004003124A0 (en) 2004-09-30
PA8567801A1 (es) 2003-11-12
WO2003074050A1 (fr) 2003-09-12
US20030207924A1 (en) 2003-11-06
MA27181A1 (fr) 2005-01-03
EA200400943A1 (ru) 2005-02-24
CO5601012A2 (es) 2006-01-31
EP1482935B1 (fr) 2008-08-20
AR038881A1 (es) 2005-02-02
ATE405260T1 (de) 2008-09-15
DE60323060D1 (de) 2008-10-02
KR20040091693A (ko) 2004-10-28
BR0308277A (pt) 2004-12-28

Similar Documents

Publication Publication Date Title
TNSN04168A1 (fr) Derives de thiazole et d'oxazole qui modulent l'activite de ppar
TNSN04167A1 (fr) Derives de thiazole et d'oxazole qui modulent l'activite de ppar
MA27189A1 (fr) Composes qui modulent l'activite de ppar et procedes pour leur preparation
TNSN99171A1 (fr) 4-carboxyamino-2-substitue-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant
MA25809A1 (fr) Derives d'arylmethylamine pour usage comme inhibiteurs de tryptase
MA26723A1 (fr) Acides oxamiques nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
EP1562897A4 (fr) Inhibiteurs de beta-secretase phenylcarboxamide utilises dans le traitement de la maladie d'alzheimer
NO913923L (no) 17beta-substituerte-4-aza-5alfa-androstan-3-on-derivater ogfremgangsmaate ved fremstilling av disse
MA26697A1 (fr) Composes nouveaux inhibiteurs de gsk-3 et compositions pharmaceutiques les contenant
WO2001090104A3 (fr) Derives de 1-(pyrrlolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone
NO2007010I2 (no) Sitagliptin, eventuelt i form av et farmasøytisk akseptabelt salt
WO2005004802A3 (fr) Inhibiteurs de la beta-secretase a base de n-alkyle phenylcarboxamide pour le traitement de la maladie d'alzheimer
IL149150A0 (en) 2-(4-(6-methoxy-naphthalene-2-yl)-5-pyridin-4-yl-1h-imidazole-2-yl)-2-methyl-derivatives, pharmaceutical compositions comprising them and use thereof as tie2 receptor kinase inhibitors
TNSN98112A1 (fr) Composes dipeptidiques
TNSN97193A1 (fr) Amides inhibiteurs de secretion de apo b/mtp, procede pour leur preparation et compositions pharmaceutiques les contenant.
HUP0000130A2 (hu) 1,3-Heterociklusos fémproteáz inhibitorok
MA26701A1 (fr) PYRAZOLOPYRIMIDINONES NOUVELLES INHIBITRICES DE PDE-5 GMPc, PROCEDE POUR LEUR PREPARATION ET COMPOSTIONS PHARMACEUTIQUES LES CONTENANT.
TNSN98185A1 (fr) Derives d'isoquinoleine nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26741A1 (fr) Suspensions de ziprasidone nouvelles et procede pour leur preparation.
BR9503572A (pt) Composto composiçao farmaceutica e método de tratamento ou prevençao de uma doença
MA26732A1 (fr) Composition pharmaceutique nouvelle comprenant un inhibiteur de nos, et procede pour sa preparation
MA26725A1 (fr) Derives de resorcinol, compositions pharmaceutiques les contenant et procede pour leur preparation
NO20000771D0 (no) Anvendelse av fankinon for behandling av Alzheimers sykdom
MX9701116A (es) Profarmacos de 5-(2-[4-(1,2-benzoisotiazol-3-il)-1-piperazinil]etil)-6-clor o-1,3-dihidro-2h-indol-2-ona.
IL113706A (en) N-hydroxyurea alkyl phenyl oxazoles and thiazoles uses thereof as anti-inflammatory agents and pharmaceutical compositions containing them